GNI GROUP LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,247 JPY | -0.27% |
|
+3.93% | -20.60% |
| Sales 2024 * | 39.62B 254M | Sales 2025 * | 50.4B 323M | Capitalization | 113B 722M |
|---|---|---|---|---|---|
| Net income 2024 * | 7.13B 45.76M | Net income 2025 * | 10.4B 66.77M | EV / Sales 2024 * | 2.84 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.23 x |
| P/E ratio 2024 * |
15.7
x | P/E ratio 2025 * |
10.8
x | Employees | 843 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.62% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -0.27% | ||
| 1 week | +3.93% | ||
| Current month | +2.00% | ||
| 1 month | -7.03% | ||
| 3 months | -26.33% | ||
| 6 months | -26.45% | ||
| Current year | -20.60% |
1 week
2 089.00
2 283.00
1 month
2 030.002 583.00
Current year
2 030.003 865.00
1 year
1 091.003 865.00
3 years
918.003 865.00
5 years
903.674 070.00
10 years
390.004 070.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ying Luo
FOU | Founder | 57 | 05-05-31 |
Toshiya Kitagawa
DFI | Director of Finance/CFO | - | 23-07-02 |
Kanichiro Suzuki
BRD | Director/Board Member | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hao Yan
BRD | Director/Board Member | 61 | - |
Hideaki Sashiwa
BRD | Director/Board Member | 66 | 08-05-31 |
Ying Luo
FOU | Founder | 57 | 05-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.52% | 24 M€ | -16.63% | ||
| 0.01% | 775 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-12 | 2,247 | -0.27% | 394 100 |
| 24-06-11 | 2,253 | +3.16% | 886,200 |
| 24-06-10 | 2,184 | +0.55% | 618,000 |
| 24-06-07 | 2,172 | +3.23% | 352,800 |
| 24-06-06 | 2,104 | -0.89% | 541,800 |
Delayed Quote Japan Exchange, June 12, 2024 at 02:00 am EDT
More quotes
GNI Group Ltd is a Japan-based company engaged in pharmaceutical business and medical device business. The Company conducts global pharmaceutical research and development, manufacturing and distribution and biomaterials business. The Company operates in two business segments. The Pharmaceuticals segment conducts research and development, manufacturing, and sale of developed compounds, including ETUARY sold in the China market and Hydronidone (F351), which is in clinical trials. The main products also include other pharmaceuticals and reagents. The Medical Devices segment develops, manufactures, and sells medical devices such as biomaterials in the United States. This segment also includes medical device Designated Marketing Authorization Holder (DMAH) and In-Country Caretaker (ICC) services. The Company also conducts clinical and business development in the United States and conducts clinical development of F351 for Metabolic Dysfunction-Associated Steatohepatitis in the United States.
Calendar
2024-08-11
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2,247
JPY
Average target price
4,100
JPY
Spread / Average Target
+82.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.60% | 716M | |
| +48.57% | 56.87B | |
| +37.15% | 39.72B | |
| -6.06% | 39.27B | |
| -6.90% | 28.73B | |
| +13.40% | 26.21B | |
| -15.96% | 19.79B | |
| +32.70% | 12.28B | |
| +27.86% | 12.23B | |
| +0.72% | 12.12B |
- Stock Market
- Equities
- 2160 Stock
